Collectively, these results indicate that diminished CGI-58 in macrophages, liver, and adipose tissue driven by CGI-58 ASO treatment or deficiency of CGI-58 in myeloid cells has minimal effects on atherosclerosis progression. The gene discussed is ABHD5; the disease is atherosclerosis.